Straits Times Index
3,090.31 +17.32 (+0.56%) Nikkei
33,431.51 -55.38 (-0.17%) Hang Seng
16,830.30 -212.58 (-1.25%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
39,411.73 +677.54 (+1.75%) CMC Crypto 200
802.76 +11.20 (+1.41%)
Kyowa Kirin Co., Ltd. (KYKOF)
| Previous close | 16.35 |
| Open | 16.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 16.35 - 16.35 |
| 52-week range | 16.06 - 22.85 |
| Volume | |
| Avg. volume | 741 |
| Market cap | 8.851B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 22.40 |
| EPS (TTM) | 0.73 |
| Earnings date | N/A |
| Forward dividend & yield | 0.41 (2.50%) |
| Ex-dividend date | 28 Dec 2023 |
| 1y target est | N/A |
CNW GroupKyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023.
CNW GroupKyowa Kirin North America Assumes Commercial Leadership Role for (Pr)CRYSVITA™ (Burosumab Injection) in North America
Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a top 50 global specialty pharmaceutical company, today assumes primary commercial leadership for PrCRYSVITA™ (burosumab injection) in the United States and Canada from Ultragenyx Pharmaceutical, Inc., a transition planned for from the start of their decade-long collaboration. Initially discovered and developed by Kyowa Kirin, CRYSVITA is used for the treatment of X-linked hypophosphataemia (XLH) in adult and pedi
- Business Wire
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
SAN DIEGO & TOKYO, December 05, 2022--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing glob
